Top in endocrinology: Obesity treatment for adolescents, CV benefits of diabetes drugs
Click Here to Manage Email Alerts
The FDA recently expanded the approval of liraglutide for chronic weight management in adolescents with obesity. It was the top story in endocrinology last week.
Another top story was about the risks and potential benefits of SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 1 diabetes.
Read these and more top stories in endocrinology below:
FDA approves liraglutide for treating obesity in adolescents
The FDA approved an updated label for liraglutide (Saxenda, Novo Nordisk), which can now be used in adolescents aged 12 to 17 years with a body weight of at least 60 kg and an initial BMI corresponding to 30 kg/m² or greater for adults. With the updated label, liraglutide 3 mg is the first FDA-approved therapy for adolescents with obesity in more than a decade. Read more.
Experts debate CV benefit of type 2 diabetes drugs for adults with type 1
Type 2 diabetes agents with proven cardiovascular benefit may be useful for patients with type 1 diabetes to prevent atherosclerotic CVD, but more robust data are needed for the type 1 population, according to two speakers who debated the issue. Read more.
Diabetes technology, social determinants of health updates top ADA 2021 Standards of Care
The American Diabetes Association published its 2021 Standards of Care, with new evidence-based updates ranging from diabetes technology and self-management education to socioeconomic disparities and COVID-19 vaccine recommendations. Read more.
Menstrual cycle tracking app may increase odds for conception
Women who use an app to track their menstrual cycle may increase their likelihood of becoming pregnant, according to study data published in Human Reproduction. Read more.
Early menarche, fewer CV health metrics increase risk for type 2 diabetes
Women from China who had early menarche were more likely to develop type 2 diabetes as adults, with the risk higher for those with nonideal cardiovascular health, according to data from the REACTION study. Read more.